Fukuda Tetsuya

Affiliation and department：

Research field (1)： Hematology and oncology

Research theme for competitive and other funds (5)：

2010 - 2012 Analysis of oncogenic mechanisms incuced by receptor tyrosine kinase receptor, ROR1
2006 - 2007 The functional analysis of receptor tyrosine kinase, ROR1 in B cell malignancy
2002 - 2003 造血器腫瘍細胞の細胞周期停止とアポトーシス制御のシグナル伝達機構の解明
2001 - 2002 BCL6及びその関連遺伝子BAZFの血球分化における機能解析
1998 - 2000 Bcl6遺伝子及びその関連遺伝子のリンパ球における生理的機能と癌化機構の解析

Papers (64)：

Yuki Hatayama, Kanako Watanabe, Hitomi Ichikawa, Koji Kawamura, Tetsuya Fukuda, Toru Motokura. Differential Reactivation of Cytomegalovirus and Epstein-Barr Virus in Patients with B Cell Lymphoma. Viral Immunology. 2023
Yuki Hatayama, Yukari Endo, Nao Kojima, Noriko Yamashita, Takuya Iwamoto, Hiroya Namba, Hitomi Ichikawa, Koji Kawamura, Tetsuya Fukuda, Toru Motokura. Construction of an Automatic Quantification Method for Bone Marrow Cellularity Using Image Analysis Software. Yonago acta medica. 2023. 66. 2. 322-325
Takuya Iwamoto, Yuki Hatayama, Hiroya Namba, Nao Kojima, Takuya Horie, Noriko Yamashita, Hitomi Ichikawa, Tetsuya Fukuda, Toru Motokura. Fibrin monomer complex as a potential thrombosis marker related to venous thromboembolism risk in pregnant women. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2023. 60. 4. 279-285
Sayaka Suzuki, Satoshi Kuwamoto, Koji Kawamura, Michiko Matsushita, Toru Motokura, Yuzuru Hosoda, Masaya Maegaki, Rina Hosoda, Kentaro Hara, Yoshihisa Umekita, et al. Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma. Yonago acta medica. 2023. 66. 1. 56-66
Rina Hosoda, Koji Kawamura, Kentaro Hara, Masaya Maegaki, Sayaka Suzuki, Yuzuru Hosoda, Shota Morishita, Hiroki Chikumi, Toru Motokura, Tetsuya Fukuda. [Fatal invasive pneumococcal disease developed 14 years after allogeneic hematopoietic stem cell transplantation in a patient with myelodysplastic syndrome]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2023. 64. 7. 614-618

ｍore...

MISC (7)：

Konami Kato, Yuki Hatayama, Hisashi Shimohiro, Hitomi Ichikawa, Tetsuya Fukuda. DIFFERENCES IN THE COMPOSITION OF ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) REAGENTS AFFECT CLOT WAVEFORM ANALYSIS. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY. 2023. 45. 81-82
畑山祐輝, 渡部加奈子, 市川ひとみ, 福田哲也, 本倉徹. B細胞性リンパ腫患者におけるCMVとEBVの再活性化の臨床的差異. 医療検査と自動化(Web). 2022. 47. 4
N. Takahashi, K. Nishiwaki, C. Nakaseko, H. Wakita, K. Sano, C. Ohwada, N. Aotsuka, J. Kuroki, H. Kimura, H. Noji, et al. SUCCESSFUL TREATMENT FREE REMISSION IN CML AFTER 2 YEAR CONSOLIDATION WITH NILOTINIB OF AN MR4.5 RESPONSE LEVEL ACHIEVED ORIGINALLY WITH IMATINIB TREATMENT: FIRST REPORT FROM STAT2 TRIAL IN JAPAN. HAEMATOLOGICA. 2016. 101. 61-61
Ayako Arai, Ken-ichi Imadome, Mayumi Takahashi, Koichi Naka, Tetsuya Fukuda, Shigeyoshi Fujiwara, Osamu Miura. CD137 Expression Is Enhanced in EBV-Infected T or NK Cells by Viral Protein LMP1 and Mediates Anti-Apoptotic Intracellular Signaling through NF-kappa B Activation. BLOOD. 2009. 114. 22. 765-766
高橋真由美, 今留謙一, 中昂一, 福田哲也, 小山高敏, 藤原成悦, 三浦修, 新井文子. Epstein-Barr virus感染TおよびNK細胞にはCD137が発現し抗アポトーシスシグナルを伝達する. 臨床血液. 2009. 50. 9. 896-896

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page